Uzbekistan cough syrup deaths: In the newest developments to Uzbekistan cough syrup deaths, the Uttar Pradesh authorities have cancelled the manufacturing licence of Noida-based pharmaceutical firm ‘Marion Biotech’ on Wednesday, March 22. Dok-1, a cough syrup manufactured by Marion Biotech, was linked to the deaths of 18 youngsters in Uzbekistan. The incident that occurred in December 2022 spurred an investigation by the central and state narcotics authorities in India.
“The firm’s licence was under suspension since January after which a detailed inquiry was initiated. Now the licence of the firm has been cancelled by the Uttar Pradesh Drugs Controlling and Licensing Authority. The firm can no longer manufacture the syrup,” a authorities official mentioned, PTI reported.
The manufacturing licence of the firm was suspended in January after inspections at its website by the central and state drug authorities within the wake of the controversy.
WHO issued a ‘medical product alert’
On January 12 this 12 months, the World Health Organization (WHO) had additionally issued a ‘medical product alert’, referring to 2 substandard (contaminated) merchandise, recognized in Uzbekistan and reported to it on December 22, 2022.
Earlier on March 3, the Noida Police had arrested three workers of Marion Biotech from its workplace in Sector 67 whereas a lookout discover was issued for 2 of its administrators after an FIR was lodged towards all of them.
ALSO READ: Uzbekistan cough syrup deaths: 3 officers of Noida-based pharma firm arrested
Marion Biotech’s medication pattern discovered to be substandard
The FIR had come within the wake of the investigation’s discovering that samples of Marion Biotech’s medication had been “adulterated” and “not of standard quality.” The samples had been despatched to the federal government’s regional drug testing laboratory in Chandigarh and 22 of them had been discovered to be ‘not of standard quality’ (adulterated and spurious), based on the FIR.
It ought to be famous right here that the FIR has been lodged beneath Indian Penal Code sections 274 (adulteration of medication), 275 (sale of adulterated medication), 276 (sale of drug as a special drug or medical preparation) in addition to beneath Section 17 (misbranded medication) and associated violations of the Drugs and Cosmetics Act, 1940.
(With PTI inputs)
